Introduction
Injectable subcutaneous (s.c.) therapies are well-established first-line multiple sclerosis (MS) treatments and the benefits of autoinjectors in the application of these treatments are widely accepted. As for other therapies, adherence may influence treatment success. 1, 2 Besides efficacy of a therapeutic strategy, major factors for patient adherence to the prescribed medication and satisfaction with self-administered injections are ease of application as well as acceptable side-effect profiles. 2 In addition, MS worsening might induce deteriorations in cognitive and fine-motor skills which interfere with manual injection and subsequently with adherence. Interferon beta preparations have been available for decades and extensively tested for efficacy and safety. Over time, these agents underwent improvements with respect to injection tolerability as well as handling (e.g., titration at therapy initiation). 2, 4 The invention of injection devices reduced the need for manual injection [5] [6] [7] [8] [9] [10] and its use significantly reduced the occurrence of injection site reactions. 11 Moreover, their use was found to be a predictor of adherence. 12 Autoinjection devices simplify MS therapy and often provide additional features to improve patient comfort and adherence. These features comprise reminder functionsas forgetfulness is a major obstacle for self-administered therapies 2,3,13 -simplicity, adjustability of injection speed and depth, optical and acoustic signaling at the beginning/ end of the injection process, hidden needle, low-force safety release to ensure the device is positioned on the skin correctly at the time of injection, and an LED-display for visualization of the injection progress. 6, 8, 10, 14, 15 Several autoinjection devices for application of immunomodulatory drugs are currently available in the MS market and characterized by different handling, features, and design. Among these, the Betaconnect ® (Medicom Innovation Partner A/S, Struer, Denmark) and the RebiSmart™ (Ares Trading SA, Coinsins, Switzerland) are the only electronic devices in the MS therapy field, all others are mechanical devices. 8, 14 Recently in a survey of US patients, the electronic Betaconnect autoinjector has been rated higher than mechanical devices. 15 In this market survey, the purpose was to investigate patients' evaluation of autoinjectors typically used for the application of s.c. interferon beta formulations: the Betaconnect and the RebiSmart electronic autoinjectors as well as the ExtaviPro™ (Owen Mumford Ltd., Oxford, UK) mechanical autoinjection device.
Material and methods Participants
This market survey was conducted with 100 MS patients from five German cities (Berlin, Frankfurt, Hamburg, Cologne, and Munich) between February and April 2016. The participants were selected via a screening questionnaire containing questions about age, gender, MS diagnosis, medication, and autoinjector use. All participants signed a written informed consent form for this survey. The initial 15 participants served for validation of the questionnaire. After the validation, video instructions were presented to the patients to ensure that every patient got the same information about each device. The main analysis group of patients (n=85) was included in data analysis. Of these participants, 39 currently used the Betaconnect autoinjector, 36 the RebiSmart, and 10 the ExtaviPro device for application of their s.c. interferon beta therapy. 
Questionnaire
The questionnaire was developed in close collaboration with Bayer Vital GmbH, Leverkusen, Germany, this information was not communicated to the participants. Questionnaire validation for comprehensibility was conducted with a subgroup of participants (n=15). Data from the validation group were collected in the same way and used for comparisons with the main group (n=85). These data were not included in overall data analysis.
All patients were asked 22 questions in the same order. Depending on the question, answers were given openly, by marking or via a rating scale (1-10, with 10 as best rating). First, participants indicated their autoinjector currently in use, and watched an instruction video -except for the validation group (n=15) where the interviewer presented the patients' own devices to them instead of video instructions. Then patients answered questions about their satisfaction with the device in use. Second, they were asked for their view of an ideal autoinjector for MS therapy. Third, participants watched instruction videos for the two devices currently not in use (except for the validation group [n=15] where the interviewer presented the two devices currently not in use to the patients instead of video instructions) and had the opportunity to dummy-inject into a pillow. Finally, the patients were asked to compare the devices as well as their functions and to determine the preferred autoinjector, provided their current medication was suitable for all three devices ( Figure 1 , Table S1 ). 
Results

Demographic characteristics
The majority of the surveyed participants were between 18 and 55 years old (29% 18-35 years, 52% 36-55 years, 18% 56-75 years) and 68% were female. Among participants, 63 had relapsing-remitting MS, 6 had secondary progressive MS, and 16 patients could not specify their MS type. The participants of the validation group were younger, 80% were female, and only from one location (Table 1) .
Currently, 39 participants used the Betaconnect, 36 the RebiSmart, and 10 the ExtaviPro device. Four of the 85 patients (5%) had earlier experiences with one of the autoinjectors assessed in this survey (Betaconnect [n=2], RebiSmart [n=1], and ExtaviPro [n=1]). There were 14 patients in the main group and 2 patients in the validation group who had used other injection devices not part of this market research.
satisfaction with autoinjector currently in use
Before presentation of the devices not in use, participants were asked to rate the level of satisfaction with their own device on a scale (1= not satisfied at all, 10= very satisfied). There were 82% of the Betaconnect users who were highly satisfied with their device (8-10 points, mean 8.5), as well as 67% of the RebiSmart (mean 7.9) and 60% of the ExtaviPro users (mean 7.5) ( Figure 2 ). In the validation group, 3 of 7 Betaconnect users, 3 of 5 RebiSmart users, and 1 of 3 ExtaviPro users indicated high levels of satisfaction with their device. Betaconnect users (n=39) especially appreciated ease of handling (41% of n=39), reminder for next injection (31%), low noise (18%; P,0.05 with respect to RebiSmart users), appealing design (21%) as well as leads patients clearly through the procedure (18%), and pain-free injection (18%). Among RebiSmart users (n=36), ease of handling (36%) and ease of operation (28%) were the most favored features, as well as the design (25%), leads patients clearly through the procedure (22%), and the fact that no syringe is visibly held in the hand (36%; P,0.05 with respect to Betaconnect users and ExtaviPro users). ExtaviPro users (n=10) favored that the device is handy (50%; P,0.05 with respect to Betaconnect and RebiSmart users), has an appealing design, and easy handling (30% each). Inconveniences to the disadvantage of ExtaviPro particularly concerned unpleasant noise (30%; P,0.05 with respect to Betaconnect users), size (20%; P,0.05 with respect to Betaconnect users) as well as unhandiness (20%; P,0.05 with respect to Betaconnect users), and to the disadvantage of RebiSmart, weight (17%; P,0.05 with respect to Betaconnect users) and problems with the needle (17%; P,0.05 with respect to Betaconnect users). There were 18% of the Betaconnect patients who complained about the necessity of high pressure/tension when the device is applied to the skin (multiple answers possible).
Most participants in the main analysis group and in the validation group desired improvements of their own device that concern reduction of weight/noise and enhancement of handling ( Table 2) .
Proposed features/improvements toward ideal device
As evaluated by the participants, the most important features of an ideal autoinjector comprise general ease of the injection process, uncomplicated preparation of the device before use, possibility of usage without help from others, easy determination of injection start and stop, and ease of pressing button for start of injection (Table 3 ). The patients of the validation group chose the same characteristics of an ideal autoinjector except for the fact that ease of pressing button for start of injection and intuitive handling of device were more important to them than easy determination of injection start and stop. Table 3 ). In the validation group, the patients evaluated nearly all features of the three devices higher than patients in the main analysis group. But the ease of pressing button for start of the injection (RebiSmart mean 6.8; Betaconnect mean 8.6) and the minimal noise during injection (RebiSmart mean 7.0; Betaconnect mean 7.9) received a lower valuation for RebiSmart and Betaconnect from the patients of the validation group. The rating for the ease of applying enough pressure for starting injection (mean 6.1) and handiness of RebiSmart during injection process (mean 6.0) as well as the reminder function (mean 7.3) and uncomplicated preparation of Betaconnect before use (mean 6.5) were also lower than in the main analysis group.
In 
Total evaluation of all three injection devices
After presentation of all devices, participants ranked the injection devices with respect to the preferred autoinjector. On the assumption that their own medication was suitable for all three autoinjectors, 56% of the participants (n=48/85) 
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Autoinjector preference for Ms therapy chose the Betaconnect, 36% the RebiSmart (n=31/85), and 5% the ExtaviPro device (n=4/85); 2% did not answer (n=2/85). Thus, after device presentation, in total 9 Betaconnect non-users in the main analysis group would now prefer switching from RebiSmart (total loss; n=5) and ExtaviPro (total loss; n=6) to this autoinjector (Figure 4) , provided their own medication was suitable for the Betaconnect device. A total of 8 patients of the validation group would prefer the Betaconnect, 2 patients the RebiSmart, and 5 patients the ExtaviPro autoinjector.
Discussion
Use of autoinjection devices is well-established in selfadministered therapies (e.g., s.c. interferon beta formulations) and might help contribute to improved adherence, which is a hallmark for treatment success. 2, 12 A variety of surveys has evaluated patient satisfaction with electronic and mechanical autoinjectors as well as manual injection to date. [8] [9] [10] [14] [15] [16] [17] [18] [19] In our survey, we queried patient needs and preferences with respect to current electronic (Betaconnect, RebiSmart) and mechanical (ExtaviPro) autoinjectors. These are autoinjectors typically available in Europe for s.c. interferon beta formulations. To our knowledge, a side-by-side evaluation of the available autoinjectors has not been performed before. In this survey, it is the first time that participants received video presentation of all evaluated devices and the possibility to dummy-inject with the two devices not used by the patient to enable objective evaluation of the device in current use and the comparator devices.
Initially, survey participants were largely satisfied with their current device in use -with slightly more satisfied Betaconnect users. These data were received before video presentation and dummy-testing of the two devices not in use. In addition, only 5% of the participants had prior experiences with one of the other two autoinjectors in this market survey. Thus, indicated satisfaction levels were mainly independent of function and features provided by the devices not in use, and participants at this time were not aware of advantages or disadvantages of their device in comparison to the other two devices.
According to our findings, the ideal injection device leads patients through the process with sufficient and clear menu guidance, accompanied by visual and acoustic signaling. Easy assembly of the device, handiness (rendering patients independent from the help of others), adjustable injection settings, and no presence of disturbing noise or movement are important features as well as a hidden needle without necessity of manual retraction. Further details concern the prevention of disposable products, presence of an easily rechargeable battery, and a reminder function for upcoming injections. Some of these aspects have also been rated important in other patient surveys. 5, 6, 8, 10, 14, 15 Besides convenienceassociated factors, some features might have direct impact on treatment adherence: since forgetfulness as well as needle-phobia are important obstacles to adherence, 3,10 a reminder of upcoming injections and a comfortable injection process (without manual needle retraction) could generally be an advantage.
Among the tested devices, the Betaconnect was rated significantly higher by non-users with respect to most queried features and closest to the participants' ideal, which is in line with recent survey findings comparing the Betaconnect device with autoinjectors licensed in the US. Appreciated features (including overall easy injection process, handiness, and adjustability of injection) were similar to our data. 15 However, a few improvements to the Betaconnect were recommended in our survey (e.g., concerning disposable and visible needle, sensitivity of the contact sensor). RebiSmart and ExtaviPro users mentioned lack of sufficient handiness of their devices. With respect to the mechanical ExtaviPro device, non-users particularly miss those features appreciated regarding the other electronic devices (e.g., sufficient signaling, reminder function).
Considering these findings, it is not surprising that after testing the devices, some participants (n=9) would switch to the Betaconnect, provided their own medication was suitable, and in return, the number of ExtaviPro and RebiSmart users would decline. It is debatable whether these participants were initially already less satisfied with their device in use or if they preferred to switch after discovering the advantages offered by the Betaconnect device. Recent data indicate that patients did not miss certain features in their device before a simulated injection with the Betaconnect autoinjector. Presence of these features (e.g., adjustable injection speed, quietness of injection) were rated high by the same patients. 15 A major issue in the treatment of chronic diseases is adherence. 20 Treatment support by autoinjectors might help contribute to high medication adherence. A study published in 2011 showed that autoinjectors were baseline predictors of adherence. Patients using an autoinjector at baseline and during the study were more adherent than patients not having used a device. 12 Furthermore, the use of the autoinjector is positively associated with quality of life. 21 Addressing adherence is not only a matter of the dosage form, but particularly of perceiving patients' needs in terms of education (necessity of long-term treatment, realistic expectations), 2 support (support programs, MS nurse, electronic diary with reminder function), 2, [21] [22] [23] and convenience (ideal autoinjection device). Nowadays it has become more and more usual for patients to track health data on their own and share data with health care providers. The Betaconnect device offers the possibility to transfer the injection data into the myBETAapp ® for the patient. This assists patients in self-management of their injection therapy. The patient can share his or her injection data through the app with the health care providers. The RebiSmart also allows data sharing between patient and health care professionals. Mechanical autoinjectors like the ExtaviPro lack the technology to save and share injection-related data.
Despite oral therapies in MS, injectable treatment options like the beta interferons for s.c. administration, have an important value in the MS therapy algorithm and will continue to cover therapeutic needs. S.c. application is not limited to MS therapy, but an application option in many therapeutic areas like oncology. The monoclonal antibodies rituximab and trastuzumab used to be delivered by the intravenous route, but later s.c. formulations were developed to improve patients' comfort. Recent studies have demonstrated that s.c. injections can shorten administration times, offer resource benefits, and improve patient convenience compared to the intravenous application route. Efficacy and tolerability did not differ from intravenous formulations. 24, 25 Therefore, with a view to the future, additional innovations of the injection devices might be important to improve patient satisfaction with injection therapy in MS and other therapeutic areas.
Conclusion
Major hallmarks in the management of chronic diseases such as MS are patient convenience and treatment adherence.
In the case of self-administered therapies, these issues are particularly addressed by development and advancement of innovative autoinjection devices which meet patients' needs. In our survey, the Betaconnect device was the most preferred autoinjector and rated closest to an ideal device. Thus, the Betaconnect might contribute to patient convenience and subsequently to improved treatment adherence. These results need to be confirmed in further studies.
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